Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

2026-04-23 15:06:04 ET

I'm initiating SELLAS Life Sciences ( SLS ) with a "Hold" rating. The reason why I'm giving this biotech this rating is because it is in the process of developing its WT1-targeting immunotherapeutic cancer vaccine galinpepimut-s [GPS] for the treatment of patients with acute myeloid leukemia [AML] after 2nd complete remission [CR2] in the ongoing phase 3 REGAL trial. The primary endpoint of this trial is that of overall survival [OS]. The basis of this is that this primary analysis is event-driven and that the company believes that the 80th event is set to happen in the 1st half of 2026. The company is set to announce such an event when it does happen, after which a database lock will occur, and subsequent data will be released afterward....

Read the full article on Seeking Alpha

For further details see: